A consortium led by CardiacBooster in partnership with FIRE1 and Integer Holdings was awarded €9.3 million in DTIF funding to develop CardiacBooster’s unique mechanical cardiac support technology into a comprehensive medical device platform for the treatment of cardiogenic shock. The consortium aims to bring significant innovation in an indication where mortality rates have remained too high over the past few decades. The Disruptive Technologies Innovation Fund, established under Ireland’s National Development Plan, is directed at investments in bold ideas and ambitious collaborative partnerships that have the potential to deliver real impact. CardiacBooster and the consortium aim to improve health outcomes and prevent loss of life by providing interventional cardiologists with the therapeutic tools they need to improve survival rates in cardiogenic shock.